Content about Carl Icahn

August 19, 2011

Icahn Enterprises is continuing its pursuit of Clorox, despite the company's rejection of last month's takeover bid.

OAKLAND, Calif. — Icahn Enterprises is continuing its pursuit of Clorox, despite the company's rejection of last month's takeover bid.

Icahn Enterprises' affiliate High River Limited Partnership said Friday that Icahn Enterprises is looking to replace Clorox's entire board of directors with 11 nominees, who will stand for election at Clorox's yet-to-be-announced annual stockholders meeting.

July 19, 2011

Clorox has turned down an acquisition proposal from Icahn Enterprises valued at $76.50 per share, the company's board of directors announced Monday.

OAKLAND, Calif. — Clorox has turned down an acquisition proposal from Icahn Enterprises valued at $76.50 per share, the company's board of directors announced Monday.

Clorox's board, in consultation with its financial and legal advisers, concluded that the offer "substantially undervalues the company and is neither credible nor adequate," Clorox chairman and CEO Don Knauss wrote to Icahn Enterprises chairman Carl Icahn, adding that Clorox is committed to continued stockholder value creation. The company received the offer July 14.

July 15, 2011

Clorox on Friday confirmed it has received an unsolicited conditional proposal from Icahn Enterprises to acquire the company for $76.50 per share, subject to due diligence, financing and other conditions.

OAKLAND, Calif. — Clorox on Friday confirmed it has received an unsolicited conditional proposal from Icahn Enterprises to acquire the company for $76.50 per share, subject to due diligence, financing and other conditions. Clorox said its board of directors, in consultation with its financial and legal advisers, will review the proposal in due course. 

Goldman, Sachs & Co. and J.P. Morgan Securities are serving as financial advisers, and Wachtell, Lipton, Rosen & Katz is legal adviser.

May 6, 2010

Billionaire investor Carl Icahn is trying to kick Genzyme CEO Henri Termeer off the company’s...

March 22, 2010

Biogen Idec appointed a nominee of billionaire investor Carl Icahn to its board Monday, the...

May 14, 2009

It isn’t often that one of America’s premier retail companies finds itself the subject of...

NEW YORK It isn’t often that one of America’s premier retail companies finds itself the subject of a determined battle for management control by a disgruntled shareholder. That’s especially true for a retail giant with an enviable track record, a highly regarded management team and a resoundingly successful niche strategy.